Construction of a biocompatible decellularized porcine hepatic lobe for liver bioengineering

International Journal of Artificial Organs

Volumn 38, Issue 2, 2015, Pages 96-104

  Hussein, Kamal H ^a   Park, Kyung M ^a   Kim, Hyun M ^a   Teotia, Pankaj K ^a   Ghim, Jinn H ^a   Woo, Heung M ^a,b  

^a Kangwon National University   (South Korea)

^b HARVARD STEM CELL INSTITUTE   (United States)

Author keywords

Biocompatbility; Biodegradability; Cytotoxicity; Decellularization; Immunogenicity; Scaffold

Indexed keywords

ANTIGENS; BIOCOMPATIBILITY; BIODEGRADATION; CYTOTOXICITY; DISEASES; ENZYME ACTIVITY; SCAFFOLDS (BIOLOGY); SODIUM DODECYL SULFATE; SULFUR COMPOUNDS;

BIOCOMPATBILITY; CELL-BE; CELL/B.E; CELL/BE; CLINICAL USE; DECELLULARIZATION; DECELLULARIZED; IMMUNOGENICITY; PATHOGENICS; XENOTRANSPLANTATION;

BIODEGRADABILITY;

BIOMATERIAL; COLLAGENASE; DODECYL SULFATE SODIUM; GENOMIC DNA;

ADULT; ANIMAL TISSUE; ARTICLE; BIOARTIFICIAL LIVER; BIODEGRADATION; BIOENGINEERING; BLOOD VESSEL PARAMETERS; CHEMICAL ANALYSIS; CONTROLLED STUDY; CYTOTOXICITY; DECELLULARIZATION; DNA CONTENT; EXTRACELLULAR MATRIX; GRAFT REJECTION; HISTOLOGY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; NONHUMAN; PATHOGENICITY; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PORTAL VEIN; SCANNING ELECTRON MICROSCOPY; SWINE; THROMBOSIS; TISSUE SCAFFOLD; XENOTRANSPLANTATION; ANIMAL; ARTIFICIAL LIVER; CYTOLOGY; DRUG EFFECTS; GRAFT SURVIVAL; GROWTH, DEVELOPMENT AND AGING; HEPG2 CELL LINE; HUMAN; IMMUNOLOGY; LIVER; LIVER TRANSPLANTATION; METABOLISM; PIG; PROCEDURES; TIME; TISSUE ENGINEERING; TRANSPLANTATION TOLERANCE; XENOGRAFT;

ANIMALS; BIOCOMPATIBLE MATERIALS; COLLAGENASES; EXTRACELLULAR MATRIX; GRAFT REJECTION; GRAFT SURVIVAL; HEP G2 CELLS; HETEROGRAFTS; HUMANS; LIVER; LIVER TRANSPLANTATION; LIVER, ARTIFICIAL; SODIUM DODECYL SULFATE; SUS SCROFA; TIME FACTORS; TISSUE ENGINEERING; TISSUE SCAFFOLDS; TRANSPLANTATION TOLERANCE; TRANSPLANTATION, HETEROLOGOUS;

EID: 84928162346     PISSN: 03913988     EISSN: 17246040     Source Type: Journal    
DOI: 10.5301/ijao.5000394     Document Type: Article

References (30)

1. Soltys KA, Soto-Gutiérrez A, Nagaya M, et al. Barriers to the successful treatment of liver disease by hepatocyte transplantation. J Hepatol. 2010;53(4):769-774.
2. Hoshiba T, Lu H, Kawazoe N, Chen G. Decellularized matrices for tissue engineering. Expert Opin Biol Ther. 2010;10(12): 1717-1728.
3. Sprangers B, Waer M, Billiau AD. Xenotransplantation: where are we in 2008? Kidney Int. 2008;74(1):14-21.
4. Ekser B, Gridelli B, Tector AJ, Cooper DK. Pig liver xenotransplantation as a bridge to allotransplantation: which patients might benefit? Transplantation. 2009;88(9):1041-1049.
5. Mattiuzzo G, Takeuchi Y, Scobie L. Potential zoonotic infection of porcine endogenous retrovirus in xenotransplantation. Methods Mol Biol. 2012;885:263-279.
6. Fishman JA, Scobie L, Takeuchi Y. Xenotransplantation-associated infectious risk: a WHO consultation. Xenotransplantation. 2012;19(2):72-81.
7. Hussein KH, Park KM, Teotia PK, et al. Fabrication of a biodegradable xenoantigen-free rat liver scaffold for potential drug screening applications. Transplant Proc. 2013;45(8):3092-3096.
8. Booth C, Soker T, Baptista P, et al. Liver bioengineering: current status and future perspectives. World J Gastroenterol. 2012;18(47):6926-6934.
9. Hussein KH, Park KM, Teotia PK, et al. Sterilization using electrolyzed water highly retains the biological properties in tissue-engineered porcine liver scaffold. Int J Artif Organs. 2013;36(11):781-792.
10. Soto-Gutierrez A, Zhang L, Medberry C, et al. A whole-organ regenerative medicine approach for liver replacement. Tissue Eng Part C Methods. 2011;17(6):677-686.
11. Uygun BE, Soto-Gutierrez A, Yagi H, et al. Organ reengineering through development of a transplantable recellularized liver graft using decellularized liver matrix. Nat Med. 2010; 16(7):814-820.
12. Zhao L, Zhao J, Wang S, et al. Evaluation of immunocompatibility of tissue-engineered periosteum. Biomed Mater. 2011; 6(1):015005.
13. Crapo PM, Gilbert TW, Badylak SF. An overview of tissue and whole organ decellularization processes. Biomaterials. 2011; 32(12):3233-3243.
14. Simon P, Kasimir MT, Seebacher G, et al. Early failure of the tissue engineered porcine heart valve SYNERGRAFT in pediatric patients. Eur J Cardiothorac Surg. 2003;23(6):1002-1006.
15. Eitan Y, Sarig U, Dahan N, Machluf M. Acellular cardiac extracellular matrix as a scaffold for tissue engineering: in vitro cell support, remodeling, and biocompatibility. Tissue Eng Part C Methods. 2010;16(4):671-683.
16. Saluja R, Jyoti A, Chatterjee M, et al. Molecular and biochemical characterization of nitric oxide synthase isoforms and their intracellular distribution in human peripheral blood mononuclear cells. Biochim Biophys Acta. 2011;1813(10):1700-1707.
17. Baptista PM, Siddiqui MM, Lozier G, Rodriguez SR, Atala A, Soker S. The use of whole organ decellularization for the generation of a vascularized liver organoid. Hepatology. 2011; 53(2):604-617.
18. Park KM, Woo HM. Porcine bioengineered scaffolds as new frontiers in regenerative medicine. Transplant Proc. 2012;44 (4):1146-1150.
19. Sang L, Luo D, Xu S, Wang X, Li X. Fabrication and evaluation of biomimetic scaffolds by using collagen–alginate fibrillar gels for potential tissue engineering applications. Mater Sci Eng C. 2011;31(2):262-271.
20. Mirmalek-Sani SH, Sullivan DC, Zimmerman C, Shupe TD, Petersen BE. Immunogenicity of decellularized porcine liver for bioengineered hepatic tissue. Am J Pathol. 2013;183(2):558-565.
21. Rhodes N. Biocompatibility testing of tissue engineered products. Vox Sang. 2004;87(Suppl 2):161-163.
22. Gilbert TW, Freund JM, Badylak SF. Quantification of DNA in biologic scaffold materials. J Surg Res. 2009;152(1):135-139.
23. Park KM, Park SM, Yang SR, Hong SH, Woo HM. Preparation of immunogen-reduced and biocompatible extracellular matrices from porcine liver. J Biosci Bioeng. 2013;115(2):207-215.
24. Lin CC, Cooper DK, Dorling A. Coagulation dysregulation as a barrier to xenotransplantation in the primate. Transpl Immunol. 2009;21(2):75-80.
25. Brock LG, Delputte PL, Waldman JP, Nauwynck HJ, Rees MA. Porcine sialoadhesin: a newly identified xenogeneic innate immune receptor. Am J Transplant. 2012;12(12):3272-3282.
26. Waldman JP, Vogel T, Burlak C, et al. Blocking porcine sialoadhesin improves extracorporeal porcine liver xenoperfusion with human blood. Xenotransplantation. 2013;20(4):239-251.
27. Gilbert TW, Stewart-Akers AM, Badylak SF. A quantitative method for evaluating the degradation of biologic scaffold materials. Biomaterials. 2007;28(2):147-150.
28. Babensee JE, Anderson JM, McIntire LV, Mikos AG. Host response to tissue engineered devices. Adv Drug Deliv Rev. 1998;33(1-2):111-139.
29. Wolf MT, Daly KA, Brennan-Pierce EP, et al. A hydrogel derived from decellularized dermal extracellular matrix. Biomaterials. 2012;33(29):7028-7038.
30. Beattie AJ, Gilbert TW, Guyot JP, Yates AJ, Badylak SF. Chemoattraction of progenitor cells by remodeling extracellular matrix scaffolds. Tissue Eng Part A. 2009;15(5):1119-1125.